Please use this identifier to cite or link to this item: http://hdl.handle.net/2067/1577
DC FieldValueLanguage
dc.contributor.authorSartorius, Rossella-
dc.contributor.authorPisu, Paola-
dc.contributor.authorD'Apice, Luciana-
dc.contributor.authorPizzella, Luciano-
dc.contributor.authorRomano, Chiara-
dc.contributor.authorCortese, Giancarlo-
dc.contributor.authorGiorgini, Angela-
dc.contributor.authorSantoni, Angela-
dc.contributor.authorDe Berardinis, Piergiuseppe-
dc.contributor.authorVelotti, Francesca Romana-
dc.date.accessioned2011-03-22T19:17:28Z-
dc.date.available2011-03-22T19:17:28Z-
dc.date.issued2008-
dc.identifier.citationSartorius, R. et al. 2008. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses. "Journal of Immunology" 180 (6): 3719-3728it
dc.identifier.issn0022-1767-
dc.identifier.urihttp://hdl.handle.net/2067/1577-
dc.descriptionL'articolo è disponibile sul sito dell'editore http://www.jimmunol.orgit
dc.description.abstractDelivery of tumor-associated antigen (TAA)-derived peptides in a high immunogenic form represents one of the key issues for effective peptide-based cancer vaccine development. Here, we report the ability of non-pathogenic filamentous bacteriophage fd virions to deliver HLA-A2-restricted MAGE-A10254-262- or MAGE-A3271-279-derived peptides and elicit potent specific CTL responses in vitro and in vivo. Interestingly, human anti-MAGE-A3271-279-specific CTLs were able to kill human MAGE-A3+ tumor cells, even if these cells naturally express a low amount of MAGE-A3271-279 peptide-HLA epitope surface complexes and are usually not recognized by CTLs generated by conventional stimulation procedures. MAGE-A3271-279-specific/CD8+ CTL clones were isolated from in vitro cultures and their high avidity for antigen recognition was assessed. Moreover, in vivo tumor protection assay showed that vaccination of humanized HHD (HLA-A2.1+/H2-Db+) transgenic mice with phage particles expressing MAGE-A3271-279-derived peptides hampered tumor growth. Overall, these data indicate that engineered filamentous bacteriophage virions increase substantially the immunogenicity of delivered TAA-derived peptides, thus representing a novel powerful system for the development of effective peptide-based cancer vaccines.it
dc.language.isoenit
dc.publisherAmerican Association of Immunologistsit
dc.subjectVaccineit
dc.subjectCytotoxic T lymphocytesit
dc.subjectTumor immunologyit
dc.subjectBladder cancerit
dc.titleThe use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responsesit
dc.typeArticleit
item.grantfulltextopen-
item.languageiso639-1en-
item.fulltextWith Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeArticle-
Appears in Collections:DECOS - Archivio della produzione scientifica
Files in This Item:
File Description SizeFormat
JImmunology1577.pdf111.56 kBAdobe PDFView/Open
Show simple item record

Page view(s)

6
Last Week
0
Last month
4
checked on Jan 22, 2021

Download(s)

4
checked on Jan 22, 2021

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.